Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 4-5, 2012, Pages 127-134

  Gil Villa, A M ^a   Norling, L V ^b,c   Serhan, C N ^b   Cordero, D ^b   Rojas, M ^a   Cadavid, A ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

15 epi lipoxin A4; Anti angiogenesis; Endothelial dysfunction; Human polymorphonuclear neutrophils; Inflammation; Oxidative stress; Preeclampsia

Indexed keywords

ASPIRIN TRIGGERED LIPOXIN A4; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOXIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FATTY ACID ANALYSIS; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LIPID PEROXIDATION; NEUTROPHIL; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ADOLESCENT; ADULT; ASPIRIN; CELL ADHESION; CELLS, CULTURED; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPID PEROXIDATION; LIPOXINS; NEUTROPHILS; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

EID: 84867230281     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.08.003     Document Type: Article

References (47)

1. Meis P.J., Goldenberg R.L., Mercer B.M., et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am. J. Obstet. Gynecol. 1998, 178:562-567.
2. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin. Perinatol. 2012, 36:56-59.
3. Sacks G.P., Studena K., Sargent K., Redman C.W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am. J. Obstet. Gynecol. 1998, 179:80-86.
4. Vaughan J.E., Walsh S.W. Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens. Pregnancy 2002, 21:205-223.
5. Redman C.W., Sargent I.L. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000, 21:597-602.
6. Cadavid A., Pena B., Garcia G., et al. Heparin plus aspirin as a "single" therapy for recurrent spontaneous abortion associated with both allo- and autoimmunity. Am. J. Reprod. Immunol. 1999, 41:271-278.
7. Heyborne K.D. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am. J. Obstet. Gynecol. 2000, 183:523-528.
8. Duley L., Henderson-Smart D.J., Meher S., King J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. 2007, CD004659.
9. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231:232-235.
10. Claria J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 1995, 92:9475-9479.
11. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 2008, 3:279-312.
12. 4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb. Haemost. 2007, 97:88-98.
13. 4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br. J. Pharmacol. 2008, 153:956-965.
14. Fiorucci S., Distrutti E., Mencarelli A., et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br. J. Pharmacol. 2003, 139:1351-1359.
15. Morris T., Stables M., Hobbs A., et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 2009, 183:2089-2096.
16. Morris T., Stables M., Colville-Nash P., et al. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. USA 2010, 107:8842-8847.
17. 4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA 2002, 99:13266-13271.
18. 4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J. Immunol. 2003, 170:6266-6272.
19. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001, 2:612-619.
20. 4 receptor that is conserved in structure and function. Br. J. Pharmacol. 2003, 139:89-98.
21. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 2002, 168:5260-5267.
22. 4 stable analogues. J. Clin. Invest. 1998, 101:819-826.
23. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 1999, 104:309-316.
24. Fierro I.M., Kutok J.L., Serhan C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J. Pharmacol. Exp. Ther. 2002, 300:385-392.
25. Serhan C.N., Jain A., Marleau S., et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 2003, 171:6856-6865.
26. Higgins J.R., de Swiet M. Blood-pressure measurement and classification in pregnancy. Lancet 2001, 357:131-135.
27. Serhan C.N., Lu Y., Hong S., Yang R. Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol. 2007, 432:275-317.
28. Gutteridge J.M., Tickner T.R. The characterisation of thiobarbituric acid reactivity in human plasma and urine. Anal. Biochem. 1978, 91:250-257.
29. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1g. Scand. J. Clin. Lab. Invest. Suppl. 1968, 97:77-89.
30. Redman C.W., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol. 1999, 180:499-506.
31. Burton G.J. Oxygen, the Janus gas; its effects on human placental development and function. J. Anat. 2009, 215:27-35.
32. Serhan C.N., Haeggstrom J.Z., Leslie C.C. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 1996, 10:1147-1158.
33. Sidani M., Siddik-Sayyid S.M. Preeclampsia, a new perspective in 2011. Middle East J. Anesthesiol. 2011, 21:207-214.
34. De Wolf F., De Wolf-Peeters C., Brosens I., Robertson W.B. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am. J. Obstet. Gynecol. 1980, 137:58-70.
35. Meekins J.W., Pijnenborg R., Hanssens M., McFadyen I.R., van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 1994, 101:669-674.
36. Hayman R., Brockelsby J., Kenny L., Baker P. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J. Soc. Gynecol. Invest. 1999, 6:3-10.
37. Walsh S.W. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin. Reprod. Endocrinol. 1998, 16:93-104.
38. Knight M., Redman C.W., Linton E.A., Sargent I.L. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 1998, 105:632-640.
39. Walsh S.W. What causes endothelial cell activation in preeclamptic women?. Am. J. Pathol. 2006, 169:1104-1106.
40. Elshal M.F., McCoy J.P. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006, 38:317-323.
41. Jonsson Y., Ruber M., Matthiesen L., et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol. 2006, 70:83-91.
42. Laresgoiti-Servitje E., Gomez-Lopez N., Olson D.M. An immunological insight into the origins of pre-eclampsia. Hum. Reprod. Update 2010, 16:510-524.
43. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 1990, 87:9383-9387.
44. Chiang N., Serhan C.N. New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators with gender implications. Compr. Ther. 2006, 32:150-157.
45. Lambers M.J., Groeneveld E., Hoozemans D.A., et al. Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum. Reprod. 2009, 24:2447-2450.
46. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007, 369:1791-1798.
47. 4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 2006, 26:e14-e17.